European Emergency Use Routes for COVID-19

by | May 1, 2020 | Coronavirus, COVID-19, FDA, Medical Devices, Quality Systems, Requirements

In Europe, medical devices are regulated under the Directive 93/42/EEC—the “Medical Devices Directive” (MDD) which is annulled by the Medical Devices Regulation (MDR) (EU) No. 2017/745, whereas Personal Protective Equipment is regulated under Regulation (EU) 2016/425 (the PPE regulation), which covers the design, manufacture, and marketing of personal protective equipment.

Under normal circumstances, devices would require a notified body involvement or self-declaration of conformity depending on the risk classification of the product. In light of the pandemic and the urgency of the situation, the European Commission has allowed for medical devices and PPEs to be distributed in the EU that do not bear a CE mark and have allowed for member states to do the same.

European Commission has allowed the distribution of PPEs and medical devices that do not bear a CE mark only if the following conditions are met:1

  • PPEs are manufactured in accordance with the technical solutions outlined in Article 14 of Regulation (EU) 2016/425 or in accordance with the recommendations from the World Health Organization.
  • The Product must meet the applicable essential health and safety requirements.
  • Where non-CE marked PPE is intended to enter the EU market, the relevant market surveillance authorities evaluate the products and, if they are found to be compliant with the essential health and safety requirements laid down by the relevant regulation, they are placed on the market only for a limited period.

The EU commission has asked notified bodies to prioritize the conformity assessments of PPEs that are necessary for protection during the outbreak and the member states market surveillance authorities to focus on non-compliant PPEs or medical devices.1

The EU Commission has implemented the ‘Green lanes’ initiative, under the guidelines for border management, which recommends that all internal EU borders should stay open to allow for a free flow of essential medical supplies as well as essential medical professionals.2

We are continuously monitoring the changing regulatory landscape and we will keep you updated on the impact it has on the medical device industry.

Have questions about marketing your medical device? Call us today at 248-987-4497 or email us at info@emmainternational.com.


1EU Commission (March 2020) on conformity assessment and market surveillance procedures within the context of the COVID-19 Threat retrieved on 04/29/2020 from  https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32020H0403&from=EN

2European Commission (March 2020) on the implementation of the Green Lanes under the Guidelines for border management measures to protect health and ensure the availability of goods and essential services retrieved on 04/29/2020 from https://ec.europa.eu/transport/sites/transport/files/legislation/2020-03-23-communication-green-lanes_en.pdf

 

Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

FDA’s Refusal to Accept Process

FDA’s Refusal to Accept Process

Before the submission of a 510(k) premarket notification, the purpose of which is to notify the FDA of the manufacturer’s intent to market a medical device,[i] there is a provision for acceptance review. This review serves as a method to assess whether a submission is administratively complete and includes all necessary information for FDA to determine substantial equivalence under section 513(i) of the Federal Food, Drug, and Cosmetic (FD&C) Act (21 United States Code (U.S.C.) § 360c(i)). To establish substantial equivalence under this provision, FDA must find the same intended use as the predicate device and either have the same technological characteristics as the predicate device or appropriate clinical and scientific data necessary to establish that the device is safe and effective as the predicate device. If the Authority is unable to determine substantial equivalence due to insufficient information, it may request for additional information to make that determination. Therefore, as a part of the acceptance review, the FDA staff follows the acceptance checklist[ii] to ensure that the application is administratively complete. These administrative elements are identified as RTA items and are required to be presented. The purpose of conducting the acceptance review is for the Lead Reviewer to determine whether the 510(k) submission meets the minimum threshold of acceptability and should be accepted for substantive review.[iii]
Empowering Your Workforce through Kaizen

Empowering Your Workforce through Kaizen

Last week, I touched on the idea of involving and empowering all employees in the workplace through the corrective and preventive actions process by fostering taking initiative and a problem-solving (refer to blogpost ‘The Art of Addressing Non-Conformances in Operations’). To expand on this concept a bit further, we’re going to be looking at Kaizen–a continuous improvement strategy in which employees at all levels are also empowered to solve problems towards big gains.
FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

The pandemic has been a challenging time for all industries including the Food and Drug Administration (FDA). The FDA had to alter the manner in which it conducted its operations. One set of tools adopted by the FDA in response to COVID-19 was the remote regulatory assessment (RRAs).

Ready to learn more about working with us?

Pin It on Pinterest

Share This